Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 1.00 |
| ▸ | PPARG | P37231 | 17/20 | 1.00 |
| ▸ | PPARD | Q03181 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ragaglitazar SCHEMBL682732 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| Ragaglitazar SCHEMBL4822459 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| Ragaglitazar SCHEMBL29369224 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| Ragaglitazar SCHEMBL6283531 | 0.95 | PPARG (0.91) | PPARAPPARGPPARD | |
| Ragaglitazar SCHEMBL6283288 | 0.94 | PPARG (0.89) | PPARAPPARGPPARD | |
| Ragaglitazar SCHEMBL6281839 | 0.94 | PPARG (0.89) | PPARAPPARGPPARD | |
| Ragaglitazar SCHEMBL6281098 | 0.93 | PPARG (0.86) | PPARAPPARGPPARD | |
| Ragaglitazar SCHEMBL6281101 | 0.93 | PPARG (0.86) | PPARAPPARGPPARD | |
| Ragaglitazar SCHEMBL6820225 | 0.93 | PPARG (0.86) | PPARAPPARGPPARD | |
| Ragaglitazar SCHEMBL6824727 | 0.93 | PPARG (0.86) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3199203-B1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10335413-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180333417-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2018-11-22 | — | — | US | disclosed |
| US-9918987-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170216296-A1 | METHODS OF TREATING HYPERGLYCEMIA | CONCERT PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| EP-3199203-A1 | SUBSTITUED XANTHINE DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-2265612-B1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-3131554-A1 | METHODS OF TREATING HYPERGLYCEMIA | Concert Pharmaceuticals Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| US-20170027946-A1 | SUBSTITUTED XANTHINE DERIVATIVES | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9492457-B2 | Substituted xanthine derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-7119198-B2 | Tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2006-10-10 | — | — | US | disclosed |
| WO-2006094933-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006094942-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2006-09-14 | — | — | WO | disclosed |
| US-20060148793-A1 | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | REDDYS'S RESEARCH FOUNDATION | 2006-07-06 | — | — | US | disclosed |
| US-6939988-B1 | Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2005-09-06 | — | — | US | disclosed |
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | PHARMACIA CORPORATION (US) | 2005-01-20 | — | — | US | disclosed |
| US-20020077320-A1 | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION AND REDDY- CHEMINOR, INC. | 2002-06-20 | — | — | US | disclosed |
| EP-1049684-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2000-11-08 | — | — | EP | disclosed |
| US-6054453-A | HYPOLIPIDEMIC, ANTIHYPERGLYCEMIC USES. | REDD'S RESEARCH FOUNDATION (IN) | 2000-04-25 | — | — | US | disclosed |
| WO-1999019313-A1 | NOVEL TRICYCLIC COMPOUNDS AND THEIR USE IN MEDICINE; PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027946-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | PPARA 1726/4885PPARG 2017/4885PPARD 1372/4885 |
| US-20170216296-A1 | METHODS OF TREATING HYPERGLYCEMIA | SLC5A2, SLC5A1, GPR119 | PPARA 707/4885PPARG 698/4885PPARD 1140/4885 |
| US-10335413-B2 | Substituted xanthine derivatives | XDH, HPRT1, CXCR3 | PPARA 1726/4885PPARG 2017/4885PPARD 1372/4885 |
| US-20020077320-A1 | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | LIPC, GPR119, CPT1A | PPARA 281/4885PPARG 102/4885PPARD 308/4885 |
| US-20180333417-A1 | SUBSTITUTED XANTHINE DERIVATIVES | XDH, HPRT1, CXCR3 | PPARA 1726/4885PPARG 2017/4885PPARD 1372/4885 |
| US-20050014732-A1 | Combination of an aldosterone receptor antagonist and an anti-diabetic agent | NR3C2, REN, AGTR1 | PPARA 96/4885PPARG 122/4885PPARD 90/4885 |
| US-20060148793-A1 | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | LIPC, GPR119, CPT1A | PPARA 209/4885PPARG 73/4885PPARD 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.